While the incidence of hormone receptor-positive BC in the general population exceeds that of ER-negative/PR-negative BC, it is postulated, however, that young women treated for HL may experience premature ovarian failure related to HL therapy, and therefore, their hormonal BC risk factors may differ from those in the general population. This evidence concerns the gene ESR1 and breast cancer.